Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-930 in Recalcitrant Discoid Lupus Erythematosus
NCT01466725Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Nov 2011
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tanzisertib in discoid lupus erythematosus (DLE), sponsored by Celgene Corporation. Started Nov 2011; status: terminated.
02
Drugs
tanzisertib
03
Conditions
discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on NCT01466725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01466725.